InMode Sued for Patent Infringement on Morpheus8 Products; Injunction & ITC Exclusion Sought
INMD sits 16% above its 52-week low of $12.72.
Summary
InMode Ltd. is facing a patent infringement lawsuit over its Morpheus8 products, with the plaintiff seeking an injunction and a parallel ITC complaint aiming for an exclusion order.
Key Events · Legal and Risk Events · INMD
-
Patent Infringement Lawsuit Filed
Serendia LLC has sued InMode and its subsidiary, Invasix Inc., in federal court for infringing four U.S. patents related to microneedling dermatological treatment devices, specifically the Morpheus8 product line.
-
Injunction and Damages Sought
The lawsuit seeks unspecified monetary damages and a court injunction to bar the importation and sale of the accused Morpheus8 products.
-
Parallel ITC Complaint Filed
Serendia also filed a parallel complaint with the International Trade Commission (ITC), seeking a limited exclusion order to prevent importation and a cease-and-desist order against corresponding U.S. inventory.
-
Company to Vigorously Defend
InMode stated it intends to deny the allegations of infringement, assert that Serendia's patents are invalid, and vigorously defend against the claims in both complaints.
Analysis · INMD · Industrial Applications And Services
This is a critical development as Serendia LLC has filed a patent infringement lawsuit against InMode, specifically targeting its key Morpheus8 product line. The lawsuit seeks not only unspecified damages but also an injunction to halt the importation and sale of these products. The parallel complaint filed with the International Trade Commission (ITC) is particularly serious, as the ITC has the power to issue exclusion orders that could quickly bar InMode from importing and selling the accused devices in the U.S., posing a significant threat to a core revenue stream.
At the time of this filing, INMD was trading at $14.81 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $851.3M. The 52-week trading range was $12.72 to $16.74. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.